Amyloid Beta 25–35 induces blood-brain barrier disruption in vitro
The amyloid β-peptide (Aβ) is transported across the blood-brain barrier (BBB) by binding with the receptor for advanced glycation end products (RAGE). Previously, we demonstrated that the Aβ fraction 25–35 (Aβ25–35) increases RAGE expression in the rat hippocampus, likely contributing to its neurotoxic effects. However, it is still debated if the interaction of Aβ with RAGE compromises the BBB function in Alzheimer’ disease (AD). Here, we evaluated the effects of Aβ25–35 in an established in vitro model of the BBB. Rat brain microvascular endothelial cells (rBMVECs) were treated with 20 μM active Aβ25–35 or the inactive Aβ35–25 (control), for 24 h. Exposure to Aβ25–35 significantly decreased cell viability, increased cellular necrosis, and increased the production of reactive oxygen species (ROS), which triggered a decrease in the enzyme glutathione peroxidase when compared to the control condition. Aβ25–35 also increased BBB permeability by altering the expression of tight junction proteins (decreasing zonula occludens-1 and increasing occludin). Aβ25–35 induced monolayer disruption and cellular disarrangement of the BBB, with RAGE being highly expressed in the zones of disarrangement. Together, these data suggest that Aβ25–35-induces toxicity by compromising the functionality and integrity of the BBB in vitro.
KeywordsAmyloid β fraction 25–35 Blood-brain barrier Oxidative stress Permeability RAGE Zonula occludens 1
These studies were supported by FDA/NCTR, E0763101, and postdoctoral fellowships from the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the FDA (to E. Cuevas). The authors are grateful to John Talpos for support in preparing this manuscript.
The views and the information in this article is solely the responsibility of the authors and is not a formal dissemination of information by the U.S. Food and Drug Administration and does not represent agency position or policy.
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
- Bednarczyk J, Lukasiuk K (2011) Tight junctions in neurological diseases. Acta Neurobiol Exp (Wars) 71(4):393–408Google Scholar
- Cuevas E, Lantz SM, Tobon-Velasco JC, Newport GD, Wu Q, Virmani A, Ali SF, Santamaria A (2011) On the in vivo early toxic properties of A-beta 25-35 peptide in the rat hippocampus: involvement of the receptor-for-advanced glycation-end-products and changes in gene expression. Neurotoxicol Teratol 33(2):288–296CrossRefGoogle Scholar
- Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B (2003) RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9(7):907–913CrossRefGoogle Scholar
- Deane R, Singh I, Sagare AP, Bell RD, Ross NT, LaRue B, Love R, Perry S, Paquette N, Deane RJ, Thiyagarajan M, Zarcone T, Fritz G, Friedman AE, Miller BL, Zlokovic BV (2012) A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 122(4):1377–1392CrossRefGoogle Scholar
- Guimaraes CC, Oliveira DD, Valdevite M, Saltoratto AL, Pereira SI, Franca Sde C, Pereira AM, Pereira PS (2015) The glycosylated flavonoids vitexin, isovitexin, and quercetrin isolated from Serjania erecta Radlk (Sapindaceae) leaves protect PC12 cells against amyloid-beta25-35 peptide-induced toxicity. Food Chem Toxicol 86:88–94CrossRefGoogle Scholar
- Kubo T, Nishimura S, Kumagae Y, Kaneko I (2002) In vivo conversion of racemized beta-amyloid ([D-Ser 26]A beta 1-40) to truncated and toxic fragments ([D-Ser 26]A beta 25-35/40) and fragment presence in the brains of Alzheimer's patients. J Neurosci Res 70:474–483Google Scholar
- Mackic JB, Stins M, McComb JG, Calero M, Ghiso J, Kim KS, Yan SD, Stern D, Schmidt AM, Frangione B, Zlokovic BV (1998) Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J Clin Invest 102(4):734–743CrossRefGoogle Scholar
- Millucci L, Ghezzi L, Bernardini G, Santucci A (2010) Conformations and biological activities of amyloid beta peptide 25-35. Curr Protein Pept Sci 11:54–67Google Scholar
- Paik S, Somvanshi RK, Kumar U (2018) Somatostatin maintains permeability and integrity of blood-brain barrier in beta-amyloid induced toxicity. Mol NeurobiolGoogle Scholar
- Perez-Severiano F, Salvatierra-Sanchez R, Rodriguez-Perez M, Cuevas-Martinez EY, Guevara J, Limon D, Maldonado PD, Medina-Campos ON, Pedraza-Chaverri J, Santamaria A (2004) S-allylcysteine prevents amyloid-beta peptide-induced oxidative stress in rat hippocampus and ameliorates learning deficits. Eur J Pharmacol 489(3):197–202CrossRefGoogle Scholar
- Provias J, Jeynes B (2014) The role of the blood-brain barrier in the pathogenesis of senile plaques in Alzheimer's disease. Int J Alzheimers Dis 2014:191863Google Scholar
- Qosa H, LeVine H 3rd, Keller JN, Kaddoumi A (2014) Mixed oligomers and monomeric amyloid-beta disrupts endothelial cells integrity and reduces monomeric amyloid-beta transport across hCMEC/D3 cell line as an in vitro blood-brain barrier model. Biochim Biophys Acta 1842(9):1806–1815CrossRefGoogle Scholar
- Rosas-Hernandez H, Cuevas E, Escudero-Lourdes C, Lantz SM, Sturdivant NM, Imam SZ, Sarkar S, Slikker W Jr, Paule MG, Balachandran K, Ali SF (2018a) Characterization of uniaxial high-speed stretch as an in vitro model of mild traumatic brain injury on the blood-brain barrier. Neurosci Lett 672:123–129CrossRefGoogle Scholar
- Wan W, Cao L, Liu L, Zhang C, Kalionis B, Tai X, Li Y, Xia S (2015) Abeta(1-42) oligomer-induced leakage in an in vitro blood-brain barrier model is associated with up-regulation of RAGE and metalloproteinases, and down-regulation of tight junction scaffold proteins. J Neurochem 134(2):382–393CrossRefGoogle Scholar
- Yan SD, Chen X, Fu J, Chen M, Godman G, Stern D, Schmidt AM (1996a) RAGE: a receptor upregulated in Alzheimer's disease on neurons, microglia, and cerebrovascular endothelium that binds amyloid-beta peptide and mediates induction of oxidant stress. Neurology 46(2):23005–23005Google Scholar
- Zhang JX, Xing JG, Wang LL, Jiang HL, Guo SL, Liu R (2017) Luteolin inhibits fibrillary beta-Amyloid1-40-induced inflammation in a human blood-brain barrier model by suppressing the p38 MAPK-mediated NF-kappaB signaling pathways. Molecules 22(3)Google Scholar